Lenvatinib

Cross-source consensus on Lenvatinib from 1 sources and 3 claims.

1 sources · 3 claims

How it works

In NEO-ERA-01, lenvatinib is administered at 8 mg daily, started on Day 5 of each neoadjuvant cycle. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
Lenvatinib contributes anti-angiogenic activity and may modulate the tumor immune microenvironment. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
Preclinical synergy and phase II data support combining lenvatinib with chemotherapy and PD-L1 inhibition before surgery. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial